Group 1 - Luzhou Laojiao announced a cash dividend of 45.92 RMB per 10 shares for the 2024 fiscal year, totaling approximately 6.759 billion RMB [1] - The dividend will be distributed to all shareholders registered by the close of trading on August 7, 2025, with the ex-dividend date set for August 8, 2025 [1] Group 2 - Huatian Technology plans to establish a wholly-owned subsidiary, Nanjing Huatian Advanced Packaging Co., Ltd., with a total registered capital of 2 billion RMB to engage in 2.5D/3D integrated circuit packaging and testing [2] - The investment will be shared among its subsidiaries, with Huatian Jiangsu contributing 1 billion RMB (50%), Huatian Kunshan 665 million RMB (33.25%), and Advanced No. 1 335 million RMB (16.75%) [2] Group 3 - China Petroleum Engineering's subsidiary received a project award letter for a seawater pipeline project in Iraq, valued at approximately 18.032 billion RMB (2.524 billion USD) [3] - Successful signing and implementation of the project could enhance the company's market position in Iraq and the Middle East, positively impacting revenue and profit over the next 4-5 years [3] Group 4 - Jinghe Integrated is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [4] - The H-share issuance will not change the company's controlling shareholder or actual controller [4] Group 5 - Huate Dain's subsidiary signed an exclusive distribution agreement for melatonin granules (Manlejing®) with Japan's Nobori Pharmaceutical, set to be approved for sale in mainland China by July 2025 [5] - This product will be the first melatonin formulation approved for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders in China [5] Group 6 - Baotai announced that its innovative drug BAT5906, a humanized monoclonal antibody injection, received clinical trial approval for new indications related to retinal conditions [6] - The drug has completed various phases of clinical trials for other indications and is preparing for further studies [6] Group 7 - Chipone Technology expects a revenue of approximately 584 million RMB for the second quarter, reflecting a quarter-on-quarter growth of 49.9% [7] - Qianli Technology reported July automobile sales of 10,200 units, a year-on-year increase of 142.34% [7] Group 8 - Hanma Technology's truck sales in July reached 956 units, marking a year-on-year growth of 42.69% [8] - Tianyi New Materials anticipates a net loss of 190 million to 240 million RMB for the first half of the year [8] Group 9 - Yabian Chemical signed a supply strategic agreement with Heng Rui Pharmaceutical [9] - Weisheng Information won procurement projects totaling 110 million RMB from South Grid and State Grid [9] - Dongjie Intelligent received a procurement order from PTT LOGISTICS SDN BHD worth approximately 62.5 million RMB [9]

格隆汇8月1日｜百奥泰(688177.SH)公告称，公司收到国家药监局核准签发的关于在研药品重组抗VEGF 人源化单克隆抗体注射液(BAT5906)新增视网膜中央静脉阻塞所致黄斑水肿(CRVO-ME)和病理性近视的 脉络膜新生血管(pmCNV)的《药物临床试验批准通知书》。BAT5906已获批临床试验的适应症包括新生 血管性年龄相关性黄斑变性(w-AMD)、糖尿病性黄斑水肿(DME)、CRVO-ME和pmCNV。目前，公司已 完成BAT5906在w-AMD适应症的I、II、III期临床研究，DME适应症已完成II期临床，CRVO-ME和 pmCNV适应症也在II/III期临床研究准备阶段。 ...